DailyStocks Stock Article Search

https://www.fool.com/earnings/call-transcripts/2024/04/25/merck-mrk-q1-2024-earnings-call-transcript/?source=iedfolrf0000001 Apr 25, 2024 - MRK earnings call for the period ending March 31, 2024. 0

https://www.zacks.com/stock/news/2262673/astrazeneca-azn-q1-earnings-sales-beat-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2262673 Apr 25, 2024 - AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs. 0

https://www.zacks.com/stock/news/2259557/how-should-you-play-merck-mrk-stock-ahead-of-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2259557 Apr 22, 2024 - Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings. 0

https://www.zacks.com/stock/news/2257704/merck-mrk-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2257704 Apr 18, 2024 - Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2257229/merck-mrk-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2257229 Apr 17, 2024 - In the most recent trading session, Merck (MRK) closed at $125.37, indicating a +0.25% shift from the previous trading day. 0

https://www.zacks.com/commentary/2255375/top-analyst-reports-for-microsoft-novo-nordisk-united-parcel?cid=CS-ZC-FT-research_daily-2255375 Apr 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS). 0

https://www.zacks.com/stock/news/2253502/moderna-mrna-up-6-on-upbeat-data-from-cancer-jab-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253502 Apr 10, 2024 - Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer. 0

https://www.zacks.com/stock/news/2253234/company-news-for-apr-10-2024?cid=CS-ZC-FT-corporate_summary-2253234 Apr 10, 2024 - Companies in The News Are: MRNA, MRK, COIN, BN, NEOG 0

https://www.zacks.com/stock/news/2252285/merck-mrk-begins-phase-ii-ii-ovarian-cancer-study-on-adc-drug-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252285 Apr 08, 2024 - Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer. 0

https://www.zacks.com/stock/news/2250526/genprex-gnpx-expands-sclc-study-of-key-candidate-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250526 Apr 04, 2024 - Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients. 0